Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM.

@article{Coletta2003ClinicalTU,
  title={Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM.},
  author={Alison P. Coletta and John G. F. Cleland and Nick Freemantle and Huan P. Loh and Anwar Ahmed Memon and Andrew L Clark},
  journal={European journal of heart failure},
  year={2003},
  volume={5 5},
  pages={
          697-704
        }
}
This article contains a series of reports on recent research developments in the field of heart failure. Reports of key presentations made at the European Society of Cardiology meeting, held in Vienna, Austria, between 30 August and 3 September 2003 are reported. In the CHARM study, candesartan reduced cardiovascular deaths and hospital admissions for heart failure, both in patients who were already taking an ACE-inhibitor and in those who were ACE intolerant. However, results in patients with… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Fighting against sudden death: A single or multidisciplinary approach

  • Journal of Interventional Cardiac Electrophysiology
  • 2006
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

697–704 valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin converting enzyme inhibitors

A. P. Coletta
  • The European Journal of Heart Failure
  • 2003

Effects of candesartan in patients with chronic heart failure and reduced left - ventricular systolic function taking angiotensin converting enzyme inhibitors : the CHARM - Added trial

McMurray JJV, J Ostergren, K Swedberg
  • Lancet
  • 2003

Efficacy and safety of oral candesartan cilexatil in patients with congestive heart failure

Cleland JGF, A Baksh, A Louis
  • Eur J Heart Fail
  • 2003

Similar Papers

Loading similar papers…